中西医结合临床研究所

【概况】

中西医结合临床研究所为上海中医药大学和上海市中医药研究院附设性机构，依托上海中医药大学附属岳阳中西医结合医院建立，是“十一五”国家中医药管理局重点学科—中西医结合临床学科的建设团队，是上海中医药大学中西医结合学科、上海市中西医结合高原学科建设的重要单元之一，是上海市高校重点实验室建设项目承担单位之一，也是上海中医药大学中西医结合临床专业硕、博士培养点之一。

2009年上海中医药大学批准成立中西医结合临床研究所。2010至2020年由原复旦大学附属华山医院王文健教授担任所长；岳阳中西医结合医院张腾教授担任副所长（主持工作），从零起步，建设研究所科学研究平台、组建专职研究团队；2012年起研究所组建临床分子药理实验室，由陈瑜教授担任实验室主任至今，负责专职科研团队的科学研究工作；2020年至今由张腾教授担任所长，原岳阳中西医结合医院临床研究中心主任王珂研究员（现上海中医药大学研究生院副院长）担任副所长。

中西医结合临床研究所专职研究团队2010年起由张腾教授负责组建，以开展自主与可持续医学科学研究为目标，由中医学、中西医结合、中药学、生物学等跨学科多专业融合的专职研究人员组成。目前研究所专职科研团队成员10名，其中高级职称6人，中级职称2人，初级职称2人；博士研究生导师3位，硕士研究生导师1位。

中西医结合临床研究所以疾病为导向，聚焦重大疑难疾病机制及中医药干预科学内涵的阐释，致力于心血管疾病、代谢性疾病、眼底病等复杂疾病的中西医结合临床基础与转化应用研究，以及针刺麻醉临床疗效评价和作用机制的研究。

研究所成立以来，专职研究团队成员主持承担各级各类科研与人才项目70余项，包括国家自然科学基金项目16项、上海市优秀学术带头人计划2项、东方学者2项，东方学者跟踪计划2项、浦江计划2项、曙光计划1项、上海市卫生系统“百人计划”1项等。

研究所组建专职研究团队的同时，建设并常规运行涵盖组织病理学、细胞及分子生物学等医学研究常用技术手段的开放平台，为临床医学研究人员提供科研指导和平台支撑。同时，开展中西医结合临床专业硕、博士研究生的高质量科学研究培训。

研究所成立以来，在高血压、慢性心力衰竭等心血管疾病以及致盲性视网膜退行性疾病等领域，取得了一系列病理机制以及中医药干预效应科学内涵相关阶段性研究进展。代表性研究成果包括：（1）首次揭示循环microRNA-505参与高血压病理形成的病理生理学意义，为高血压发生发展及靶器官损伤相关机制提供了新认识，同时为高血压靶器官损伤早期预警提供了新的生物学标志物。（2）首次报道高血压肠道淋巴管损伤的新表征，整合前期系列研究工作，首次提出肠道是高血压的靶器官之一的新认识，创新性地提出了高血压性肠病（Hypertensive intestinopathy）的新概念；在此基础上首次报道了中医药干预高血压肠道屏障改变的作用及机制，丰富了中医药有效干预高血压靶器官损伤的科学内涵。（3）揭示了转录因子KLF2调控中性粒细胞激活及免疫微血栓形成，参与心肌肥大及心衰进展的新的病理生理学意义，为心衰病理形成增加新的机制认识的同时，为慢性心衰的干预提供了新的靶点和思路。（4）揭示了G蛋白偶联受体功能性改变参与视网膜光感受器退行性病变病理形成的新机制，为该类疾病的干预提供了新的治疗靶点；首次提出将系统药理学的研究理念应用于视网膜退行性病变的干预研究，为视网膜光感受器退行性病变治疗新方案的形成提供了实验依据，也为复杂性疾病的防治研究提供了新的参考；揭示了经典明目方药防治视网膜光感受器退行性病变的有效性及作用机理，为中医药干预视网膜退行性疾病的临床应用提供了新的科学依据。代表性研究成果以第一作者及通讯作者单位发表在Journal of Clinical Investigation（同期发表学术评论）, Science Signaling（封面文章）, Annual Review of Pharmacology and Toxicology, Journal of Neuroinflammation, Angiogenesis, International Journal of Cardiology等领域内权威期刊。

研究所专职研究团队发表第一作者和/或通讯作者学术论文170余篇，其中SCI论文73篇，影响因子10分以上论文2篇。已获各级科技奖励10余项，包括中国中西医结合学会科学技术奖一等奖，上海市科技进步奖二等奖，上海中西医结合科学技术奖一等奖等。

研究所专职研究团队作为主编、副主编及编委参与编写国家级教材4部，获得国家发明专利授权9项，获得上海市药品监督管理局医疗机构应用传统工艺配制中药制剂备案1项。

培养的硕、博士研究生中，5人次获上海市优秀毕业生，1人次获上海市研究生优秀成果（学位论文），7人次获上海中医药大学优秀博士学位论文，4人次获上海中医药大学优秀硕士学位论文，3人次获岐黄杯全国中医药博士生优秀论文一等奖、1人次获岐黄杯全国中医药博士生优秀论文三等奖，1人次获岐黄杯全国中医药博士生优秀论文提名奖。

【联系方式】

地址：上海市虹口区甘河路110号

电话：021-65161782-3140

E-mail: wangpeiwei@shutcm.edu.cn

The Clinical Research Institute of Integrative Medicine

Our responsibilities

The Clinical Research Institute of Integrative Medicine was founded in 2009. Our major responsibilities are as follows:

1. Focusing on disease-oriented research, the professional research team is primarily dedicated to performing sustainable clinical, basic and translational research to address the mechanisms associated with TCM-guided prevention and treatment of complex diseases including cardiovascular diseases, metabolic disorders and retinal degenerative diseases as well as the clinical value of acupuncture anesthesia.

2. Our research team provides support to physician scientists who are interested in performing related biomedical research.

3. We conduct high-quality graduate training for the next generation biomedical researchers in integrated traditional Chinese and Western medicine.

Our achievements

The laboratory-based research team at the Clinical Research Institute of Integrative Medicine was established in 2010. We have since developed three major research units including Clinical and Molecular Medicine Unit, Clinical and Molecular Pharmacology Unit, and Acupuncture Anesthesia Unit. We’ve also established a comprehensive biomedical research capacity, which enables the researchers to carry out pathological, cellular and molecular biological studies on their own. We have chaired the key discipline of integrated traditional Chinese and Western medicine funded by the State Administration of Traditional Chinese Medicine. We have been a participating member of the key discipline of integrated traditional Chinese and Western medicine at Shanghai University of Traditional Chinese Medicine and of the Shanghai Plateau Program. Over 70 talent programs and scientific research projects have been awarded to our professional research team since the institute's establishment, including the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning, Program of Shanghai Academic/Technology Research Leader, Pujiang Talent Program, Shuguang Scholar Program, and the National Natural Science Foundation of China, etc. More than 170 research papers have been published with the research team members owning the first and/or corresponding authorship. Among these publications, 73 were published in SCI journals, including high profile journals such as Science Signaling (cover article), Journal of Clinical Investigation, Atherosclerosis, Thrombosis and Vascular Biology, Angiogenesis, International Journal of Cardiology, Journal of Biological Chemistry, and Annual Review of Pharmacology & Toxicology. The research team has received more than 10 awards, including Science and Technology Award of Chinese Association of Integrative Medicine (2013, 1^st prize), Shanghai Science and Technology Progress Award (2013, 2^nd prize), Science and Technology Award of Shanghai Association of Chinese Integrative Medicine (2016, 2018, 2020, 1^st prize), Shanghai TCM Science and Technology Award (2019, 1^st prize), and Science and Technology Award of Shanghai Association of Chinese Integrative Medicine (2021). We have received 9 authorized Chinese invention patents, among which Jingqin Pingmai Granule was registered by Shanghai Municipal Drug Administration to be officially used as a traditionally formulated prescription in hospital.

Our ongoing activities

In addition to a continued research focus on elucidating the mechanisms of cardiovascular, metabolic, neurodegenerative diseases, etc., we are actively probing the mechanisms associated with the therapeutic effects of TCM in the prevention and treatment of cardiovascular, metabolic and neurodegenerative diseases. We are also carrying out clinical and basic research on acupuncture anesthesia. 

Our staff

We have 10 registered members on staff. Dr. Teng Zhang is currently the director and Dr. Ke Wang is the vice-director of the institute. Dr. Yu Chen, the director of the Clinical Molecular Pharmacology Laboratory of the institute, is fully responsible for the scientific research of the team. The full-time research members have the educational and research background in traditional Chinese medicine, integrated traditional Chinese and Western medicine, biology, Chinese materia medica and acupuncture. Six members hold doctorate degree, two members hold master degree and two members hold bachelor degree. Currently, we have 3 professors, 3 associate professors, 1 research associate and 3 research assistants on the research team.

Contact Us

Telephone: 021-65161782-3140

Fax: 021-65161782

E-mail: wangpeiwei@shutcm.edu.cn 

Address: 110 Ganhe Rd, Shanghai 200437, China